期刊文献+

硝苯地平控释片联合缬沙坦治疗对2型糖尿病肾病合并高血压患者血清学指标的影响 被引量:4

Effects of Nifedipine Controlled Release Tablets Combined with Valsartan on Serum Indexes in Patients with Type 2 Diabetic Nephropathy and Hypertension
下载PDF
导出
摘要 目的探究硝苯地平控释片联合缬沙坦治疗对2型糖尿病肾病合并高血压患者血清学指标的影响。方法择2016年10月—2019年10月内该院76例2型糖尿病肾病合并高血压患者为对象。基于自主原则成立参照及实验两组。参照组予硝苯地平控释片,实验组予硝苯地平控释片与缬沙坦,对比两组血清学指标。结果实验组CysC、Hcy、m ALB、血压指标水平(0.54±0.08)mg/L、(6.65±0.77)μmol/L、(26.11±2.63)mg/L、(79.25±5.57)mmHg、(125.49±5.38)mmHg及HbA1c、SCr、BUN、空腹血糖水平及餐后2 h血糖水平(5.04±0.61)%、(60.32±4.78)μmol/L、(5.19±0.11)mmHg、(5.54±0.62)mmHg、(7.37±1.26)mmHg相较于参照组(1.21±0.04)mg/L、(10.24±1.36)μmol/L、(55.37±3.48)mg/L、(90.32±6.37)mmHg、(136.27±6.45)mmHg、(7.31±0.81)%、(68.23±5.12)μmol/L、(6.45±0.17)mmHg、(9.01±0.78)mmHg、(14.17±2.61)mmHg均呈现显著优越性,差异有统计学意义(t=25.385、28.721、68.525、12.246、12.348、17.571、15.036、22.147、17.158、22.208,P<0.05)。结论2型糖尿病肾病合并高血压患者应用硝苯地平控释片联合缬沙坦治疗疗效显著,能有效改善患者血清学指标。 Objective To investigate the effect of nifedipine controlled-release tablets combined with valsartan treatment on serological parameters in patients with type 2 diabetic nephropathy complicated by hypertension.Methods A total of 76 patients with type 2 diabetic nephropathy and hypertension in the hospital from October 2016 to October 2019 were selected as subjects.Two groups of reference and experiment were established based on the principle of autonomy.The reference group was given nifedipine controlled release tablets,and the experimental group was given nifedipine controlled release tablets and valsartan,and the serological indicators of the two groups were compared.Results Experimental group CysC,Hcy,m ALB,blood pressure index level(0.54±0.08)mg/L,(6.65±0.77)μmol/L,(26.11±2.63)mg/L,(79.25±5.57)mmHg,(125.49±5.38)mmHg and HbA1c,SCr,BUN,fasting blood glucose level and 2 h postprandial blood glucose level(5.04±0.61)%,(60.32±4.78)μmol/L,(5.19±0.11)mmHg,(5.54±0.62)mmHg,(7.37±1.26)mmHg compared to the reference group(1.21±0.04)mg/L,(10.24±1.36)μmol/L,(55.37±3.48)mg/L,(90.32±6.37)mmHg,(136.27±6.45)mmHg,(7.31±0.81)%,(68.23±5.12)μmol/L,(6.45±0.17)mmHg,(9.01±0.78)mmHg,(14.17±2.61)mmHg all showed significant superiority,and the difference was statistically significant(t=25.385,28.721,68.525,12.246,12.348,17.571,15.036,22.147,17.158,22.208,P<0.05).Conclusion Nifedipine controlledrelease tablets combined with valsartan are effective in patients with type 2 diabetic nephropathy and hypertension and can effectively improve the serological parameters of patients.
作者 陆伟伟 LU Wei-wei(Department of Nephrology,Sihong Kang Kidney Hospital of Jiangsu Province,Sihong,Jiangsu Province,223900 China)
出处 《糖尿病新世界》 2020年第21期64-65,68,共3页 Diabetes New World Magazine
关键词 2型糖尿病肾病 高血压 硝苯地平控释片 缬沙坦 Type 2 diabetic nephropathy Hypertension Nifedipine controlled-release tablets Valsartan
  • 相关文献

参考文献10

二级参考文献72

  • 1朱晓艳.观察采用缬沙坦联合硝苯地平控释片治疗原发性原发性高血压的临床疗效[J].医学信息(医学与计算机应用),2014(15):247-247. 被引量:4
  • 2刘小红.硝苯地平控释片联合缬沙坦治疗原发性高血压的效果观察[J].中国当代医药,2013,20(24):86-87. 被引量:17
  • 3苗迎春,张革萍.缬沙坦联合硝苯地平控释片治疗原发性高血压的临床疗效观察[J].环球中医药,2013,6(S2):146-146. 被引量:12
  • 4中国高血压防治指南修订委员会.中国高血压防治指南2010[J].中华心血管病杂志,2011,390:579-616.
  • 5Sternlicht H,Bakris GL.Management of hypertension in diabetic nephropathy:how low should we go?[J].Blood Purif,2016,41(1-3):139-143.
  • 6Sweetwyne MT,Gruenwald A,Niranjan T,et al.Notch1and Notch2in podocytes play differential roles during diabetic nephropathy development[J].Diabetes,2015,64(12):4099-4111.
  • 7Aziz KM.Correlation of urine biomarkers:microalbuminuria and spot urine protein among diabetic patients.application of spot urine protein in diabetic kidney disease,nephropathy,proteinuria estimation,diagnosing and monitoring[J].Recent Pat Endocr Metab Immune Drug Discov,2015,9(2):121-133.
  • 8Blaslov K,Bulum T,Duvnjak L.Pathophysiological factors in the development of diabetic nephropathy--new insights[J].Acta Med Croatica,2014,68(2):135-140.
  • 9Koulis C,Chow BS,McKelvey M,et al.AT2Ragonist,compound 21,is reno-protective against type 1diabetic nephropathy[J].Hypertension,2015,65(5):1073-1081.
  • 10Ruilope LM,Agarwal R,Chan JC,et al.Rationale,design,and baseline characteristics of ARTS-DN:a randomized study to assess the safety and efficacy of finerenone in patients with type2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy[J].Am J Nephrol,2014,40(6):572-581.

共引文献175

同被引文献44

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部